semaglutide indication Beware: Same Ingredients, Different FDA Indications A New Indication for Semaglutide

In the SURMOUNT-1 trial, 24-26% of participants experienced nausea at some point during the study, most commonly during dose escalation phases

The only GIP receptor antagonist administered in humans for a longer period, is the aforementioned AMG133, which is an antagonistic GIP receptor antibody conjugated to two agonistic GLP-1 receptor peptide analogues (84)

When semaglutide or tirzepatide activates these receptors, gastric emptying slows by roughly 21-34% compared to placebo, based on scintigraphy data in adults with type 2 diabetes [1]

Patients with pre-existing diabetic retinopathy should attend all scheduled eye screening appointments and report any sudden visual changes promptly